US2004208886A1PendingUtilityA1
Composition comprising a parvovirus vp1- variant and a parvovirus ns1 protein for induction of cytolysis
Est. expiryJul 10, 2021(expired)· nominal 20-yr term from priority
C07K 14/005A61K 38/162A61K 48/00A61K 2039/53C07K 2319/00C12N 2750/14322
44
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein. Furthermore, the present invention provides DNA sequences encoding said proteins. The composition of the invention is useful for the preparation of a toxin for treating tumoral diseases.
Claims
exact text as granted — not AI-modified1 . A composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein.
2 . The composition of claim 1 (a), wherein the VP1 protein is fused to a carrier protein.
3 . The composition of claim 2 , wherein the carrier protein is green fluorescent protein (GFP)
4 . The composition of claim 1 , wherein the VP1 protein is a truncated VP1 protein.
5 . The composition of claim 4 wherein the truncated VP1 protein comprises the VP1 domain exhibiting phospholipase A activity.
6 . A DNA sequence coding for the composition of claim 1 .
7 . An expression vector comprising the DNA sequence according to claim 6 .
8 . The expression vector of claim 7 , which is a parvovirus vector.
9 . The expression vector of claim 8 , which is pP4-NS1-VP1 (accession number DSM 14300) or pP4-NS1+2-P4-VP1-GFP (accession number DSN 14301)
10 . A transformant containing the expression vector according to claim 7 .
11 . A method of producing a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein, comprising:
culturing a transformant comprising an expression vector comprising a DNA sequence encoding for at least one proteins according to claim 1 under suitable conditions and isolating the protein(s) of the composition from the transformant or the medium.
12 . A pharmaceutical composition comprising the composition according to claim 1 .
13 . A method of treating tumoral diseases comprising: administering an effective amount of a composition according to claim 1 .
14 . Use of the DNA sequence according to claim 6 for the preparation of a vector for gene therapy.
15 . A composition consisting of (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein.
16 . The composition of 2, wherein the VP1 protein is a truncated VP1 protein.
17 . The composition of 3, wherein the VP1 protein is a truncated VP1 protein.
18 . A DNA sequence coding for the composition of claim 2 .
19 . An expression vector comprising the DNA sequence according to claim 18 .
20 . The expression vector of claim 19 , which is a parvovirus vector.
21 . A DNA sequence coding for the composition of claim 5 .
22 . An expression vector comprising the DNA sequence according to claim 21 .
23 . The expression vector of claim 22 , which is a parvovirus vector.
24 . A pharmaceutical composition comprising the composition according to claim 4 .
25 . A method of treating tumoral diseases comprising: administering an effective amount of a composition according to claim 4 .
26 . A pharmaceutical composition comprising the composition according to claim 5 .
27 . A method of treating tumoral diseases comprising: administering an effective amount of a composition according to claim 5 .
28 . A pharmaceutical composition comprising the DNA sequence according to claim 6
29 . A method of treating tumoral diseases comprising: administering an effective amount of the DNA sequence according to claim 6 .
30 . A DNA sequence coding for the composition of claim 5 .
31 . A pharmaceutical composition comprising the DNA sequence according to claim 30 .
32 . A method of treating tumoral diseases comprising: administering an effective amount of the DNA sequence according to claim 30.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.